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ABSTRACT 
Objectives  The objective of this study was to determine the optimal time interval for a repeated 
Chlamydia trachomatis (chlamydia) test. 
Methods  We used claims data for US women aged 15 to 25 years who were enrolled in commercial 
health insurance plans in the MarketScan database between 2002 and 2006. We determined the 
numbers of initial positive and negative tests that were followed by a repeated test, and the 
positivity of repeated tests. We used a dynamic transmission pair model that reflects the partnership 
formation and separation processes in 15 to 25 year olds to determine the time course of repeated 
infections in women under different levels of notifying the current partner. We then explored the 
additional impact of repeated testing uptake on reducing chlamydia prevalence.   
Results  40% (4,949/12,413) of positive tests were followed by a repeated test compared to 22% 
(89,119/402,659) of negative tests at any time. Positivity of repeated tests followed by an initial 
positive test was high; 15% (736) after a positive test versus 3% (2,886) after a negative test. The 
transmission model showed a peak in repeated infections between 2-5 months after treatment. For a 
chlamydia testing uptake of 10% per year, the additional impact of repeated testing on reducing 
chlamydia population prevalence was modest.  
Conclusions  Our mathematical model predictions support the recommended interval for repeat 
chlamydia testing. This study provides information that can be used to design randomised controlled 
trials to determine more effective interventions to prevent chlamydial re-infection. 
Key words: 
Chlamydia trachomatis, women, deterministic model, preventive health services. 
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Key messages: 
- Chlamydia positivity in repeated tests after an initial positive test was higher than after an initial 
negative test.  
- The mathematical model suggests a peak in the proportion of women with a repeat chlamydia 
infection between two and five months after treatment.  
- This study provides information that can be used to design randomised controlled trials to 
determine more effective interventions to prevent chlamydial re-infection.
4 
 
INTRODUCTON 
Repeated infections with Chlamydia trachomatis (chlamydia) in women are common.1 Repeated 
infections can come from treatment failure, sexual contacts with new partners, or from re-infection 
within an existing partnership. Chlamydia is the most common reported infection in most developed 
countries2 and is largely asymptomatic in both men and women.3 Chlamydia can ascend from the 
endocervix to the upper genital tract to cause pelvic inflammatory disease (PID), which is a risk factor 
for ectopic pregnancy and infertility.4 Repeated infections can increase the probability of these 
complications.5 
Many countries have adopted guidelines about repeated testing after treatment for a positive 
chlamydia test.6-10 The reasons for and the preferred timing of repeated tests vary between 
countries. In most countries, a repeated test to confirm clearance of infection (test-of-cure) is not 
recommended; see for example the guidelines from the UK,6 US,7 New Zealand9 and Scotland.10 
Reasons for doing a test of cure are: if there is doubt about whether treatment was taken;6;7;10 non-
standard treatment was given;6;9 there is a risk of re-infection;6;7;10 symptoms persist;7 or in pregnant 
women.6;7;9;10 A survey of chlamydia control activities in European countries showed that 7 countries 
recommended a repeated test as a test-of-cure.8 A repeated test to detect re-infection is 
recommended three to six months after treatment in New Zealand,9 three to 12 months after 
treatment in Scotland,10 and three months after treatment in the US.7 
Data about the optimal timing of repeated testing are inconclusive. A systematic review that 
combined repeated infection rates from different studies showed a peak in repeated infections 
between eight and 10 months after treatment.11 However, it is difficult to determine the optimal 
repeat testing interval in epidemiological studies. If a woman has a negative test after a given 
interval, one does not know whether she has had a repeated infection before and cleared it 
spontaneously. Furthermore, to our knowledge there is no randomised control trial that has 
investigated the impact of repeated testing on population prevalence. Mathematical modelling can 
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help to better understand the time course of repeat chlamydia infections in women and to assess the 
expected impact of repeated testing on population prevalence. Here, we first analyse data from 
commercially insured US women aged 15 -25 years12 to estimate positivity of repeated chlamydia 
tests. We then used a dynamic transmission model to determine the time interval during which the 
prevalence of repeated infection after treatment is highest. Finally, we estimate the additional 
impact of repeated testing on reducing population prevalence of chlamydia. 
METHODS 
Data  
We used data from US women aged 15 – 25 years enrolled in commercial health plan in the 
MarketScan database between 2002 and 2006.13 The MarketScan database links data about 
healthcare encounters and claims to detailed patient information from health plans provided by 
about 100 large employers across the USA. Details of the dataset have been described elsewhere.12 
In brief, a chlamydia test in the database was determined by using relevant Current Procedural 
Terminology codes, as recommended by the National Committee for Quality Assurance for claims 
data, or a diagnosis of chlamydia according to ICD-9 codes. We defined a month to be 32 days, as in a 
previous study.12 Any test done within one month after the initial test (irrespective of the result of 
the initial test) were not included because nucleic acid amplification tests can detect inactive DNA for 
some weeks after treatment.6;7;9;10 A positive test was determined by linking chlamydia specific 
treatment data7 to the testing data. All chlamydia specific treatments that were prescribed a month 
after the chlamydia test and all diagnoses for chlamydia were assigned as positive. This definition is 
stricter than used previously12 to avoid double counting of positive tests. All other tests were 
assumed to be negative. The reason for the test (test-of-cure, test for re-infection, testing as a result 
of partner notification or for investigation of new symptoms) was not documented.  
We determined how many tests were followed by another test one month or more after the initial 
test (repeated test). We counted the number of tests rather than women with a test, because a 
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woman can receive multiple tests. A secondary analysis using only the first two tests for each woman 
did not change the results. We calculated the interval in months between the initial and the repeated 
test (repeated test interval) stratified according to the result of the initial test. We then determined 
the percentage of repeated tests that were positive (positivity) in each month according to the result 
of the initial test. The 95% confidence intervals (CI) of the positivity after an initial positive test by 
month were calculated, assuming the normal approximation for binomially distributed data.14 
Model 
We used a compartmental pair model that explicitly describes the formation and separation of 
partnerships and thus incorporates re-infection within partnerships. The model structure has been 
described elsewhere15 and is extended here to include repeated testing and treatment failure. A 
detailed description of the extended model is given in appendix Text S1. In brief, we assume a closed 
heterosexual population of men and women aged 15 – 25 years. The behavioural model parameters 
are adapted from sexual behavioural data from the second UK National Survey of Sexual Attitudes 
and Lifestyles (Natsal 2000), a population-based cross-sectional survey,16 because not all parameters 
are available from a single national US source. We assume that 70% of all individuals are in a sexual 
partnership and the average number of new partners is 1.5 per year. These two parameters were 
used to derive an average partnership duration of 5.6 months and average gap duration of 2.4 
months (see Text S1). We assumed the partnership and gap duration to be exponentially distributed 
taking into account that some partnerships (and gaps) are very short whereas others can be long. 
Chlamydia transmission can happen within partnerships assuming one unprotected sex act per week 
and the transmission probability per sex act is calibrated to a baseline prevalence of 3%. We assume 
the infectious period to be one year.17 We also assume a short period of immunity after natural 
clearance of three months, but not after test and treatment.15;17 In the model, women are tested at a 
certain rate per year. Women can also notify their current partner. We assume that once the male 
partner is notified, he always accepts treatment. We assumed treatment to be 92% efficacious.1 In 
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the model, this value combines false negative tests; antibiotic failure; insufficient treatment taken 
and possible transmission during the time between treatment of the index case and the partner.  
The model was extended to allow a certain fraction of women who were tested positive, to have a 
repeated test three months after treatment. The interval between tests was divided into multiple 
compartments to rescale the distribution of the interval between tests from exponential towards 
constant18. Women receive a repeated test and treatment every three months until the test 
negative.  
First we use the model framework to simulate the natural history of repeated chlamydia infections to 
determine the optimal testing interval in the absence of preventive interventions. We calculate the 
proportion of women with a repeated chlamydia infection after testing and treatment in continuous 
time for different rates of partner notification uptake (see also appendix Text S1). We can then 
determine the time point at which the prevalence of repeated infection is highest (optimal testing 
interval). We also calculate the corresponding cumulative incidence of repeated infections in these 
women. We express this as the percentage of all women initially tested and treated. Second, we 
calculate the impact on reducing population prevalence of testing women at a rate of 0.1 per year 
with 50% of those women receiving a repeated test three months after treatment, or with 50% of 
the current partners being notified, or both. We repeat the analyses for a testing rate of 0.3 per year. 
Uncertainty analyses 
We performed an uncertainty analysis for the optimal testing interval. In total, 10,000 combinations 
of parameters were chosen uniformly from the parameter ranges shown in Table 1. This resulted in 
different mean partnership durations varying from almost half to double the baseline duration. Of 
those, 8,874 parameter combinations were selected based on the constraint that the per sex act 
transmission probability cannot be higher than 1. For every parameter set we obtained the optimal 
testing interval within two years after treatment. Of the 8,874 parameter sets, an additional 2 sets 
could not be used because there was no peak in the prevalence of repeated tests after two years. For 
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the remaining estimated time points the median and 0.025 and 0.975 percentiles as credible 
intervals, were obtained. 
RESULTS 
In 2.6 million women aged 15 – 25 years who were enrolled between 2002 and 2006 in the 
MarketScan database, 415,072 chlamydia tests were done.12 Of the total number of tests, 12,413 
(3%) were positive. Of the chlamydia positive tests, 40% (4,949) were followed by a repeated test at 
any time, and 25% (3,088) were done between two and five months after treatment (Figure 1A); the 
median test interval was 110 days (inter quartile range, IQR: 56 – 240 days). After a positive test, 15% 
(736) of subsequent tests were also positive, which was higher than the overall test positivity of 3% 
(Figure 1B). The median testing interval between two positive tests was 85 days (IQR: 48 – 177 days). 
Note that after one year, the number of repeated tests is low so estimates of positivity become 
unreliable.  
Repeated testing after a negative test was less frequent; 22% (89,119) of the negative tests were 
followed by a repeated test at any time. Repeated test intervals were longer than those following 
positive tests (dark area in Figure 1A); 7.7% (31,159) were done between two and five months after 
initial testing and there is a peak in the repeated testing interval around a year. The positivity in 
subsequent tests after a negative test was 3% (2,886), which is the same as in the entire dataset. The 
level of positivity was similar for all repeated testing intervals (Figure 1B). 
Using the dynamic transmission model (Figure 2A) the proportion of women with a repeat infection 
was highest (27%) 3.4 months after treatment. Chlamydia prevalence amongst previously treated 
women remains high; two years after a positive test the chlamydia prevalence in previously treated 
women is still higher than the population prevalence of 3%. Notification of the current partner 
decreases the percentage of women with a repeated infection substantially, indicating that most 
repeat infections occur in women who are still together with their infected partner (re-infections). 
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The level of partner notification amongst the women in the testing dataset was not recorded. 
However, setting partner notification uptake to 50%19 results in positivity in the model that is in good 
agreement with the 95% confidence interval of the positivity data from the MarketScan database 
from the third month. When partner notification uptake is low, transmission can happen shortly after 
treatment of the index case if they remain in a partnership with their infected partner. This is 
reflected in the cumulative incidence of repeated infections, which increases most quickly shortly 
after treatment and then levels off (Figure 2B). 
The timing of the peak in the percentage of women with a repeated infection is barely influenced by 
partner notification levels between 30% and 50%; when 50% of current partners are successfully 
notified and treated, the proportion of women with a repeat infection is highest 3.2 months after 
treatment (Figure 1A). An uncertainty analysis of the time point at which the prevalence of repeated 
infection is highest for different values of the parameter values including different levels of partner 
notification (Table 1) showed a median time interval of 3.0 months (95% credible interval: 1.1 – 5.6 
months) (Appendix Figure S2). 
At testing rates of 0.10 per year (equivalent to 9.5% of women being tested at least once every year 
on average), there is little relative additional impact in reducing population chlamydia prevalence of 
repeated testing compared to testing alone (Figure 3). Successfully treating 50% of current partners 
has a greater impact on reducing prevalence than successfully treating 50% of the women three 
months after treatment. A strategy with both partner notification and repeated testing yielded only a 
small additional reduction in population prevalence compared to doing only partner notification. The 
order of the three strategies and the additional impact on reducing population prevalence was 
similar for testing uptake of 0.30 per year (Appendix Figure S3). 
DISCUSSION 
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In the cohort studied, 25% of women with an initial positive chlamydia test had a repeat test two to 
five months later; 15% of repeat tests were also chlamydia positive. Women with an initial negative 
chlamydia test had the same level of repeat positive tests (3%) as the cohort as a whole. A dynamic 
transmission model suggests that the probability of a repeated chlamydia infection is highest two to 
five months after treatment. The estimated impact of repeated testing in women on reducing 
chlamydia population prevalence was less than the impact of notifying and treating the current 
sexual partner. 
The advantage of the MarketScan database is that there are longitudinal records of health care 
attendances and claims for services for more than two million women US women enrolled in 
commercial health insurance plans. There are, however, limitations to the analysis of data about 
repeated testing for chlamydia. First, the reasons for repeat testing are not documented in the 
dataset. This makes it difficult to know why most repeated tests amongst chlamydia positive women 
were done one to two months after the date of the initial test. Assuming a short delay between 
testing and treatment, the timing is suggestive of tests of cure, but the US Centers for Disease 
Control and Prevention guideline only recommends this in limited circumstances.7  Second, if a 
woman received her first chlamydia test shortly before leaving the insurance plan, repeated tests 
might not have been counted. Furthermore, we determined the positivity of tests by linking the test 
to treatment data. It is possible that not all women with a positive test received treatment and 
therefore that some tests were incorrectly assigned negative. However, neither limitation is likely to 
be a major source of underestimation. Limitations relating to the generalisability of the MarketScan 
data to US women in general and to underestimation to overall chlamydia testing levels through 
exclusion of tests done in other settings have been discussed in detail elsewhere.12 In this study, it is 
reasonable to assume that a woman who received a chlamydia test and treatment within her 
insurance plan is likely to have been followed up by the same physician.  
Our estimates of the percentage of women with a repeated test are very similar to other published 
estimates.20;21 An analysis of US Laboratory Corporation data from June 2008 to May 2010 from 
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women aged 15 – 34 years also showed that retesting was more common after a positive test 
compared to a negative test.21 The percentage of positive tests that was repeated was slightly higher 
(49% vs. 40%), but this might be explained by the wider age range of women studied. The difference 
cannot be explained by the inclusion of tests done ≥3 weeks after treatment because using this 
criterion in our study resulted in only 1% more repeated tests. Our estimates of the repeated testing 
uptake are in the same range as found in a recent review.20 
The advantage of the pair model for describing chlamydia transmission is that it explicitly takes into 
account the formation and separation of sexual partnerships. The model has some limitations, which 
we have discussed elsewhere.15 Since we describe the transmission of chlamydia in the general 
population, our baseline scenario assumes that the mean duration of sexual partnerships is roughly 
half a year. Partnership durations of this length permit re-infection and strongly contribute to the 
repeated infection rates. In a population with higher partner change rates, but shorter partnership 
durations, re-infection within partnerships is less likely to occur but repeated infections from new 
partners would be higher. Our uncertainty analyses, which did include shorter partnership durations, 
did not change the results. The model estimates of repeat infection rates are consistent with data 
from trials of partner notification22;23 and the cumulative incidences obtained in the model are 
consistent with published estimates.24  
The findings of our modelling study suggest that there is a critical period two to five months after 
treatment of chlamydia infection when the risk of a repeated infection is highest. This supports the 
rationale for guidelines that recommend repeat testing three to six months after treatment.7;9;10 If 
the repeated test is done too soon after treatment, many women at risk of repeated infection will 
not yet have become infected and would be falsely reassured by a negative test. If delayed too long, 
the infection might have cleared naturally but already caused upper genital tract damage. At the 
population level, however, repeat testing had little impact on reducing chlamydia prevalence 
because most chlamydia infections were in ongoing partnerships and detecting and treating these 
did not prevent much onward transmission. This is compatible with the finding of a modelling study, 
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which examined individual and population level effects of partner notification in the general 
population.25 
This study has implications for clinical management and research. In theory, partner notification 
should prevent re-infection in a person who has been treated for chlamydia. A prospective study in 
Sweden found that only 4% of people treated for chlamydia were infected six to eight months later 
after treatment and notification of an average of 3.2 partners per index case.26 The high observed 
levels of repeat chlamydia in many studies in other developed countries1;11 suggest, however, that 
either partner notification is often not done, or is not done adequately. In the UK, the average 
number of partners treated per index case is about 0.5.19 Repeat testing after treatment for 
chlamydia therefore has potential as an adjunct to partner notification. Whilst modelling studies like 
ours can give insights into the expected effects of repeat chlamydia testing and partner notification 
in reducing population prevalence, it is not known whether these will be achieved in practice. A 
systematic review of interventions to increase repeat chlamydia screening did not identify an optimal 
strategy and partner notification uptake were not reported.20 This modelling study provides 
information that can be used to design randomised controlled trials to determine the most effective 
interventions combining partner notification and intensified repeated testing to prevent chlamydial 
re-infection.
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Table 1. Parameter values for the pair model describing chlamydia transmission  
Parameter Baseline Value 
Ranges used in 
uncertainty analysis 
Behavioural parameters   
   Proportion of people in a partnership, percentage 70 50 – 90 
   Number of new partners, per year 1.5 1 – 3 
   Frequency of unprotected sex acts, per week 1 * 
Infection parameters   
   Chlamydia prevalence, percentage 3 1 – 5  
   Transmission probability, per sex act 0.1† 0 – 1† 
   Duration of infection, months 1217 6 – 18 
   Duration of immunity after natural clearance, months 315;17 1 day – 18 months 
Intervention parameters   
   Treatment failure, percentage 81 0 – 15 
   Probability of notifying the current partner 0 0 – 0.5 
   Women testing rate, per year 0.1‡ 0.3‡ 
   Duration of repeated testing interval in months 37‡  
   Repeated testing uptake, percentage 0‡ 50‡ 
* Not explicitly changed in uncertainty analyses, but indirectly by changing the transmission 
probability per sex act to obtain the desired prevalence. This can also be seen as keeping the 
transmission probability constant but changing the frequency of sex acts from 1.5 times a day to 
once a month to obtain the prevalence. 
† Calibrated to the prevalence 
‡ Parameter only used in the estimation of the population level impact (Figure 3) 
 
Figure 1. The percentage of repeated tests (A) and test positivity (B) by month split by initial test 
result (positive, n=4,949 or negative, n=89,119) in commercially insured women aged 15‐25 years 
between 2002 and 2006 in the US. Note that a month is defined as 32 days, and that all tests done 
one month after the initial test were not counted. Data are shown up to 24 months because absolute 
test numbers are low for longer intervals. 
Figure 2. Proportion of women with a repeated chlamydia infection (A) and cumulative incidence of 
repeat infections (B) after successful treatment, under different levels of partner notification (PN). 
Chlamydia prevalence in the general population was calibrated to 3%. Partner notification is 
performed for the current partner at the time of treatment of the woman. In (A) the dots denote 
positivity of repeated tests as shown in the light gray bars of Fig. 1B together with 95% confidence 
intervals. In all scenarios, the intervention parameters are set to zero, only the partner notification 
uptake at the time of index case treatment is changed from 0 to 100%. 
Figure 3. Impact of testing women for chlamydia at a rate of 0.1 per year on reducing population 
prevalence under different assumptions of the repeated testing uptake and notification of the 
current partner at the time of test and treatment. Note that the y‐axis starts at a prevalence of 2%. 
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Insights into the timing of repeated testing after treatment for 
Chlamydia trachomatis: data and modelling study  
Janneke C. M. Heijne, Sereina A. Herzog, Christian L. Althaus, Guoyu Tao, Charlotte Kent, Nicola Low. 
Detailed description of the pair model and equations: 
Test S1, Figure S1 and Table S1.  
Uncertainty analyses:  
Figures S2 and S3 
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Text S1. Pair model description 
We extended a previously published pair model.1 Here, we implemented an intervention in which a 
certain percentage of women with a positive chlamydia test () have a repeat test 1/ years after 
treatment. By subdividing the repeat testing interval into n compartments (here, n = 24), we rescale 
the distribution of this interval from exponential towards constant.2 All women that have a positive 
repeated test, are tested again after 1/ years until the test was negative. We also extended the 
previous published model by incorporating a proportion of individuals that are not successfully 
treated (1‐). All parameters are described in the following paragraph, and an overview of all 
parameters is listed in Table S1 followed by the differential equations.  
The model explicitly describes the formation of pairs (P) and the dissolution of pairs into singles (X). 
The model stratifies the population by sex with the labels f and m describing females and males 
respectively. The male and female populations are assumed to be of equal size. The infection states 
of the model are susceptible (S), infected (I) and recovered (R). In the notation of singles, the first 
subscript defines the sex of the single, the second subscript defines the infection state, and for 
women in the repeat testing programme, the third subscript denotes the compartment index of the 
repeat testing programme. In the notation of pairs, the first subscript defines the state of infection of 
the female and the second subscript defines the state of infection of the male. When the woman in a 
pair is enrolled in the repeat testing program, the index between the two infection states denotes 
the number of the compartment number of the repeat testing program. 
Pairs are formed with a pair formation rate  per year, which is calculated as the average per capita 
number of new partners per year divided by the percentage of persons who are single. Pairs separate 
with rate  per year, which is calculated as the average per capita number of new partners per year 
divided by the percentage of people in a partnership. Transmission can only occur in partnerships of 
a susceptible and infected individual with  being the number of sex acts per week, and  being the 
transmission probability per sex act. Every partnership starts with a single sexual contact. A person 
can clear the infection naturally with rate  (with 1/f being the duration of the infectious period for 
females, and 1/m for males. Note in the manuscript, f =m). After natural clearance, a period of 
immunity (1/) is assumed.  
Infected women can be tested at a rate αf per year. Of those women being tested positive, a certain 
proportion  is effectively treated. The current partner of an infected woman can be notified with a 
probability q and also a proportion of the notified partners are effectively treated (See Figure S1). 
After a positive test, a certain percentage of women () enters the repeat testing programme with or 
without performing partner notification.  
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Figure S1. Overview of the six different possibilities for treatment failure and partner notification 
after testing of the female index (αf) in a pair that consists of two infected individuals (PII). The 
symbol  denotes the proportion of tested individuals that are successfully treated (i.e. =1 means 
everybody is treated successfully) and q denotes the probability to notify the partner (i.e. q=0 means 
no partner notification). 
Table S1. List of all model parameters 
Parameter  Description 
  Transmission probability per sex act 
1/  Period of immunity after natural clearance (years) 
  Pair formation rate (per year) 
  Pair separation rate (per year) 
1/f  Duration of infectious period for females (years)  
1/m  Duration of infectious period for males (years) 
  Number of unprotected sex acts (per year) 
αf  Female testing rate (per year) 
q  Probability to notify the male partner 
  Proportion that is successfully treated 
1/  Duration of repeated testing interval (years) 
n  The number of subdivision of the repeated testing interval 
  Proportion of women that receive a repeated test 
4 
Estimation of optimal repeated testing interval 
We first estimate the proportion of women with a repeated infection over time. We do this by 
testing and treating a very small proportion of women and put them in separate compartments (the 
distribution over the different compartments is determined by treatment failure and partner 
notification uptake). The treatment of this small proportion of women hardly influences the force of 
infection. The women in the separate compartments behave exactly the same as the other women in 
the model and can form partnerships with all other males in the model. Because these women are in 
separate compartments, we can follow them up in time and calculate prevalence and incidence of 
repeated infections. We can then obtain the time interval at which the prevalence of repeated 
infections is highest (optimal time interval) in the absence of preventive interventions (i.e αf = 0, q = 0 
and  = 0).  
Estimating impact of (repeated) testing and partner notification 
We can use the set of differential equation to estimate the impact of intervention on population 
prevalence. Please note that women in the waiting period between the initial test and the repeated 
test are not eligible for another test. The four scenarios that are looked at in the paper:  
Baseline scenario, testing only:        αf = 0.1 or 0.3, q = 0 and  = 0 
Testing + partner notification:         αf = 0.1 or 0.3, q = 0.5 and  = 0 
Testing + repeated testing:         αf = 0.1 or 0.3, q = 0 and  = 0.5 
Testing + repeated testing + partner notification:   αf = 0.1 or 0.3, q = 0.5 and  = 0.5 
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The model is a system of ordinary differential equations. 
Model equation for single females: 
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Model equation for single females who receive a repeated test: 
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Model equation for pairs: 
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Model equation for pairs where the woman will receive a repeated test: 
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Uncertainty analyses 
 
Figure S2. Distribution of the time point (A) at which the proportion of repeated infection is maximal 
(peak positivity, B) calculated from 8,872 different sets of input parameters in the uncertainty 
analysis. The median optimal interval was 3.0 months (95% credible interval: 1.1 – 5.6 months). The 
median positivity was 17.5% (95% credible interval: 6.8% – 40.2%). Based on Pearson product‐
moment correlation coefficients, a high peak positivity was correlated with short duration of 
infection, low number of partners in the last year, low partner notification uptake and low treatment 
success. No other parameters were correlated
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Figure S3. Impact of testing women for chlamydia at a rate of 0.3 per year on reducing population 
prevalence under different assumptions of the repeated testing uptake and notification of the 
current partner at the time of test and treatment. 
